Outcome Analysis of Patients Treated with Gemcitabine and Nab-Paclitaxelfor Unresectable Pancreatic Cancer
We examined the treatment outcome of 17 patients who received gemcitabine (GEM) + nab-paclitaxel (nabPTX) therapy (GnP therapy) as the first-line treatment for unresectable pancreatic cancer at our hospital. Thedisease staging at the time of treatment planning was such that 3 patients had Stage IIA...
Saved in:
Published in | Journal of Nihon University Medical Association Vol. 81; no. 1; pp. 35 - 38 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | Japanese |
Published |
NIHON UNIVERSITY MEDICAL ASSOCIATION
01.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We examined the treatment outcome of 17 patients who received gemcitabine (GEM) + nab-paclitaxel (nabPTX) therapy (GnP therapy) as the first-line treatment for unresectable pancreatic cancer at our hospital. Thedisease staging at the time of treatment planning was such that 3 patients had Stage IIA disease, 4 patients hadStage III disease and 10 patients had Stage IV disease, and the resectability classification was such that 7 patientshad UR-LA and 10 patients had UR-M. The response to treatment was PR in 6 patients, SD in 8 patients and PDin 3 patients, and the response rate and disease control rate were 35.3% and 82.4%, respectively. Four patientsunderwent conversion surgery after GnP therapy. Three patients had UR-LA and one patient had UR-M. All resected patients had better overall survival than unresected patients. Conversion surgery should be attempted forpatients who have responded to multidisciplinary treatment and would tolerate surgery. |
---|---|
ISSN: | 0029-0424 1884-0779 |
DOI: | 10.4264/numa.81.1_35 |